Cell and Gene Therapy Market Opportunity Assessment
Challenge: A multinational investment firm was interested in performing an objective, third party analysis of the cell and gene therapySuccessful Initial Licensing Meetings at BIO 2020
Situation: An emerging biotech desired to connect with potential partners to explore out licensing opportunities during BIO 2020. The client,Primary Research and View of the Future
“View of the Future.” It’s critical to understand the current landscape for each client’s service offerings, but understanding what respondentsThe Disruptor26 Podcast Series with Paul Garofolo
Locus Biosciences is revolutionizing the treatment of bacterial disease using its CRISPR-Cas3 technology to kill targeted bacteria while leaving the2020 Q1 BCI – Fundamentals of Running a Biopharmaceutical
The Biopharma CEO Confidence Index is a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry’sMarket Opportunity Assessment
Situation: An innovative preclinical CRO with multiple disruptive service offerings retained Kineticos to conduct an evaluation of each of their503B Compounding Pharmacy Market Assessment
Situation: A global biopharma company was interested in a comprehensive evaluation of the 503B compounding pharmacy market. The client wasThe Role of Confirmation Bias in Decision Making
Written by Abe Maingi, VP of Precision Medicine, Kineticos Confirmation bias is our tendency to search for and favor allPrimary Research Study
Kineticos conducted primary research via KOLs and an online survey to give our client qualitative and quantitative data to supportAre we Manufacturing the right T-Cells And a Look at the Future of Oncology Precision Medicine
The final part of the discussion between Kineticos’ Operating Executive, Steve Buckanavage and Precision Biosciences’ CMO, Christopher Heery M.D., covers